Immediate Impact
53 standout
Citing Papers
MXenes in healthcare: synthesis, fundamentals and applications
2025 Standout
Hepatocellular carcinoma: signaling pathways and therapeutic advances
2025 Standout
Works of Youwei Bi being referenced
FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer
2022
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
2018
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Youwei Bi | 293 | 261 | 47 | 212 | 24 | 719 | |
| Frédéric Commo | 220 | 267 | 53 | 242 | 16 | 760 | |
| Lihua Huang | 205 | 226 | 43 | 284 | 23 | 672 | |
| Hiroyoshi Maeda | 175 | 380 | 32 | 266 | 27 | 683 | |
| Sachin Shah | 173 | 282 | 49 | 211 | 25 | 721 | |
| Kuo-Ting Chang | 431 | 320 | 8 | 205 | 22 | 730 | |
| Silvio Ken Garattini | 171 | 273 | 16 | 271 | 42 | 710 | |
| Marco Siano | 149 | 285 | 11 | 171 | 42 | 615 | |
| Ahmad Shariftabrizi | 186 | 296 | 66 | 301 | 42 | 828 | |
| Hiroshi Wakui | 326 | 396 | 11 | 223 | 38 | 781 | |
| Maria Alice Franzoi | 312 | 529 | 22 | 149 | 49 | 798 |
All Works
Login with ORCID to disown or claim papers
Loading papers...